For the p53 Special Issue
p53 Review Article
The role of TP53 in Cervical carcinogenesis†
Article first published online: 24 FEB 2003
DOI: 10.1002/humu.10178
Copyright © 2003 Wiley-Liss, Inc.
Issue
1098-1004/asset/cover.gif?v=1&s=b02ab57a64d28403f477b09d50f72a4d63f4c8eb)
Human Mutation
Special Issue: Focus on p53 and Cancer
Volume 21, Issue 3, pages 307–312, March 2003
Additional Information
How to Cite
Tommasino, M., Accardi, R., Caldeira, S., Dong, W., Malanchi, I., Smet, A. and Zehbe, I. (2003), The role of TP53 in Cervical carcinogenesis. Hum. Mutat., 21: 307–312. doi: 10.1002/humu.10178
- †
Publication History
- Issue published online: 24 FEB 2003
- Article first published online: 24 FEB 2003
- Abstract
- References
- Cited By
Keywords:
- cervical cancer;
- cancer;
- tumor;
- p53;
- TP53;
- human papilloma virus;
- HPV;
- E6-mediated p53 inactivation;
- E6AP;
- UBE3A
Abstract
Functional loss of the tumor suppressor p53 by alterations in its TP53 gene is a frequent event in cancers of different anatomical regions. Cervical cancer is strongly linked to infection by high-risk human papillomavirus (HPV) types. The viral oncoprotein E6 has the ability to associate with and neutralize the function of p53. E6 interacts with a 100-kDa cellular protein, termed E6 associated protein (E6AP; also called ubiquitin-protein ligase E3A or UBE3A), which functions as an ubiquitin protein ligase. The dimeric complex then binds p53 and E6AP catalyzes multi-ubiquitination and degradation of p53. The ability to promote p53 degradation is an exclusive property of E6 from the high-risk HPV types. Indeed, the low-risk E6 proteins lack this activity, although they can bind p53. Consistent with the E6 function of the high-risk HPV types, the majority of cervical cancer cells have a wild-type p53 gene, but the protein levels are strongly decreased. Several independent studies have shown that in a small percentage of cervical tumors the p53 gene is mutated. However, this event appears to be unrelated to the presence or absence of HPV infection and the nature of the tumor. Hum Mutat 21:307–312, 2003. © 2003 Wiley-Liss, Inc.

1098-1004/asset/HUMU_left.gif?v=1&s=4065e12063da1c0efe3c1a74d4f13c3cd92fba18)
1098-1004/asset/HUMU_right.gif?v=1&s=58026811b6aa5bee5a3d0e0563a705f8b681f34d)